MCM
LGND icon

Manchester Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Manchester Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.8K Hold
9
– – ﹤0.01% 1037
2025
Q4 		$1.7K Buy
+9
New +$1.73K ﹤0.01% 1050
2019
Q2 		– Sell
-329
Closed -$26K – 607
2019
Q1 		$26K Buy
+329
New +$24.9K ﹤0.01% 492
2015
Q1 		– Sell
-7,173
Closed -$238K – 718
2014
Q4 		$238K Buy
+7,173
New +$233K 0.03% 323

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Manchester Capital Management's LGND Position: Q1 2026 in Review

Manchester Capital Management held its Ligand Pharmaceuticals (LGND) position steady in Q1 2026 at 9 shares worth $1.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1037.

Manchester Capital Management first reported a position in LGND in Q4 2014 and has held it in 4 quarters since. The position peaked at $238K in Q4 2014. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Manchester Capital Management held 9 shares of Ligand Pharmaceuticals worth $1.8K as of Q1 2026.
  • Manchester Capital Management left its Ligand Pharmaceuticals share count unchanged in Q1 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Manchester Capital Management's portfolio in Q1 2026, its #1037 holding.
  • Manchester Capital Management first reported a position in Ligand Pharmaceuticals in Q4 2014 and has held it in 4 quarters since.
  • Manchester Capital Management's Ligand Pharmaceuticals position peaked at $238K in Q4 2014.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.